TB-500 Information & Coordination for Licensed U.S. Clinics
TB-500 is a name used for peptide substances related to a fragment of thymosin beta-4. FDA evaluated TB-500 free base and TB-500 acetate in 2026 in connection with the section 503A Bulks List.
FDA states that neither substance has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About TB-500
The name TB-500 should not be treated as though it identifies a standardized, FDA-approved medication.
FDA describes TB-500 free base as a reported seven-amino-acid synthetic fragment of thymosin beta-4. TB-500 free base and TB-500 acetate are different active pharmaceutical ingredients, and FDA has noted inconsistencies in how TB-500-related substances have been named and characterized.
This distinction matters because full-length thymosin beta-4 and TB-500 should not be presented as interchangeable substances.
FDA’s 2026 evaluation did not identify clinical studies in which TB-500 free base or TB-500 acetate was administered to patients to treat a disease or condition. FDA also found insufficient evidence to evaluate effectiveness for the wound-healing use it reviewed.
For that reason, Phoenix does not promote TB-500 for tissue repair, wound healing, inflammation, post-surgical recovery, tendon or ligament injuries, athletic recovery, or other treatment outcomes.
Current FDA and Compounding Status
FDA evaluated TB-500 free base and TB-500 acetate in 2026 for possible inclusion on the section 503A Bulks List. The agency evaluated the substances in the context of a proposed wound-healing use.
FDA concluded that the available information weighed against adding either substance to the 503A Bulks List and proposed that TB-500 free base and TB-500 acetate not be added.
That proposal should not be described as a final FDA rule by itself. FDA explains that advisory-committee recommendations are non-binding and that the agency completes its own review before making a final determination.
A pharmacy’s 503A status or an outsourcing facility’s 503B registration also does not, on its own, establish that a particular bulk substance may be used in compounding. Sections 503A and 503B impose separate conditions on bulk drug substances.
Why Product Identity Matters
TB-500 presents an additional documentation issue because the name itself has not always been used consistently.
FDA found that TB-500 is a common name rather than an established United States Adopted Name and noted that different salts, derivatives, and active moieties have been marketed using the same general terminology. FDA identified inconsistent naming as a potential patient-safety concern because the substance supplied could differ from the substance intended.
For a clinic reviewing a TB-500-related inquiry, the documentation behind the substance therefore matters.
Phoenix can help organize available records and publicly available regulatory information. We do not determine whether a substance is clinically appropriate or whether a particular preparation may legally be compounded.
How Phoenix Meds Supports Licensed Clinics
Our work is administrative.
Licensed healthcare organizations may use Phoenix for help with professional credential review, document organization, publicly available licensing and regulatory records, and communication around administrative requirements.
We can also help a clinic identify gaps or inconsistencies in the information it has received so the appropriate licensed, regulatory, or legal professional can review them.
The service is designed to reduce administrative back-and-forth without turning Phoenix into the prescribing, compounding, dispensing, or distribution party.
An administrative review is not product approval, pharmacy accreditation, a clinical recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA reports that it has not identified human-exposure data for drug products containing the thymosin beta-4 fragment identified as TB-500.
The agency also cites potential immunogenicity concerns associated with aggregation and peptide-related impurities and says important information needed to characterize potential safety issues is lacking.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of TB-500. We also do not certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
TB-500 Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding professional credential review, documentation, and regulatory information relevant to a TB-500-related inquiry. An administrative inquiry is not a medication order and does not establish product availability, compounding eligibility, FDA approval, or clinical appropriateness.
Clinic Verification
Licensed healthcare organizations may submit relevant professional and facility credentials for administrative verification.
Documentation Review
Phoenix may help organize available documentation and publicly available regulatory information so the clinic can identify matters that need further review.
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is TB-500 FDA approved?
FDA’s 2026 review states that TB-500 free base and TB-500 acetate are not components of FDA-approved drugs.
Is TB-500 the same as thymosin beta-4?
Not exactly. FDA describes TB-500 free base as a reported seven-amino-acid synthetic fragment of thymosin beta-4. Full-length thymosin beta-4 and the TB-500 substances FDA evaluated should not be presented as identical.
Is TB-500 on the 503A Bulks List?
FDA evaluated TB-500 free base and TB-500 acetate in 2026 and proposed that neither substance be included on the 503A Bulks List. FDA’s advisory process is not itself a final agency determination, so clinics should verify the current FDA status before relying on a particular compounding pathway.
Does Phoenix Meds compound or dispense TB-500?
No. Phoenix Meds Inc. does not compound, manufacture, dispense, test, ship, or take custody of TB-500.
What can Phoenix Meds help with?
Our role is administrative. We may assist with credential review, documentation organization, publicly available regulatory information, and professional communication.
Does Phoenix Meds provide TB-500 dosing or treatment protocols?
No. We do not provide patient-specific dosing, treatment protocols, or clinical recommendations.
Does Phoenix guarantee purity or sterility?
No. Phoenix does not test TB-500 or certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present TB-500 as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.